Posted by Michael Wonder on 12 Feb 2020
Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s Probuphine to their provincial drug plans in the fight against the opioid crisis
11 February 2020 - Probuphine is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plans.
Knight Therapeutics announced today that Probuphine, the first and only subdermal implant approved in Canada, is now additionally publicly funded in Quebec, New Brunswick, Newfoundland and Nova Scotia for the management of opioid dependence in patients clinically stabilised on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support.
In addition, Manitoba has announced that it will add Probuphine to the Manitoba Drug Benefits Formulary as of 2 March 2020.
